| Literature DB >> 30356429 |
M D Mauricio1, S Guerra-Ojeda1, P Marchio1, S L Valles1, M Aldasoro1, I Escribano-Lopez2, J R Herance3, M Rocha2, J M Vila1, V M Victor1,2.
Abstract
Nanotechnology has had a significant impact on medicine in recent years, its application being referred to as nanomedicine. Nanoparticles have certain properties with biomedical applications; however, in some situations, they have demonstrated cell toxicity, which has caused concern surrounding their clinical use. In this review, we focus on two aspects: first, we summarize the types of nanoparticles according to their chemical composition and the general characteristics of their use in medicine, and second, we review the applications of nanoparticles in vascular alteration, especially in endothelial dysfunction related to oxidative stress. This condition can lead to a reduction in nitric oxide (NO) bioavailability, consequently affecting vascular tone regulation and endothelial dysfunction, which is the first phase in the development of cardiovascular diseases. Therefore, nanoparticles with antioxidant properties may improve vascular dysfunction associated with hypertension, diabetes mellitus, or atherosclerosis.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30356429 PMCID: PMC6178176 DOI: 10.1155/2018/6231482
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Generalized diagram of the types of nanoparticles and their main biomedical applications. Based on their chemical composition, nanoparticles can be divided into three main groups: organic, inorganic, and carbon-based. Each category includes several types of nanoformulations.
Figure 2The Nox 4 paradox. Vascular Nox 4 generates superoxide anion (O2−) and hydrogen peroxide (H2O2). Depending on which via predominates, Nox 4 activation can be damaging or protective. VSCMs: vascular smooth muscle cells.
Figure 3Endothelial dysfunction due to oxidative stress. The image shows how vascular oxidative stress leads to endothelial dysfunction. (a) represents the production of nitric oxide (NO) from L-arginine by endothelial nitric oxide synthase (eNOS) in a healthy endothelium, where levels of superoxide anion (O2−) are low. NO diffuses from the endothelium to the vascular smooth muscle, where it activates soluble guanylate cyclase (sGC), which increases the levels of guanosine 3′,5′ cyclic monophosphate (cGMP), thus leading to vasodilation. (b) represents acute vascular oxidative stress, with an increase in O2− production, followed by an increase in peroxynitrite (ONOO−) levels. ONOO− produces endothelial dysfunction by directly reducing the NO available for activating sGC and by reducing prostaglandin I2 (PGI2) content via nitration PGI2 synthase. If oxidative stress is persistent (c), eNOS becomes uncoupled, producing O2− instead of NO and aggravating endothelial dysfunction.
Figure 4Chronic activation of the renin-angiotensin system (RAS) contributes to oxidative stress and vascular dysfunction. Increased levels of angiotensin II (AT II) lead to endothelial dysfunction through AT II receptor 1 (AT1R) activation, which in turn induces vascular oxidative stress by increasing NADPH oxidase (Nox) activity and xanthine oxidase (XO) expression. Both enzymes produce superoxide anion (O2−), which scavenges nitric oxide (NO) by forming peroxynitrite (ONOO−), consequently decreasing NO bioavailability and causing endothelial dysfunction. Moreover, AT II can undermine the induction of the antioxidant system thioredoxin (TRX), enhancing levels of H2O2 and contributing to vascular oxidative stress. H2O2 is the most stable and abundant ROS which, as a signalling messenger, maintains physiologic vascular homeostasis, but its overproduction is related to vascular dysfunction. In contrast, AT II receptor 2 (AT2R) activation can counteract the lesser NO bioavailability induced by vascular oxidative stress via eNOS phosphorylation, thereby increasing its activity.
Figure 5Effects of nanoparticles on the main mechanisms of vascular oxidative stress and antioxidant systems. Mitochondrial respiratory chain enzymes, xanthine oxidase (XO), NADPH oxidase (Nox), and uncoupled endothelial NO synthase (eNOS) are the main sources of superoxide anion (O2−) in the vascular wall. O2− can produce hydroxil radical (OH), hydrogen peroxide (H2O2), and peroxynitrite (ONOO−). The enzymes that decompose H2O2 are catalase, glutathione, thioredoxin peroxidase, and peroxiredoxin. In inflammation, the induction of iNOS produces high levels of NO which react with mitochondrial respiratory chain enzymes and increase O2− production. Some nanoparticles (NPs), such as nanoceria, have demonstrated the ability to reduce the expression of iNOS. Moreover, nanoceria can scavenge both NO and OH, thus proving to be anti-inflammatory and antioxidant agents. Some NPs increase Nox activity and can be used as antitumoral agents. The role of Nox 4 in vascular function is controversial; whereas some studies report a protective role against atherogenesis, others show the contrary. Certain NPs can be used as NO donors to reverse endothelial dysfunction. Some NPs exert SOD, catalase, oxidase, phosphatase, and peroxidase-mimetic activities.
Nanoparticles and their biological effects.
| References | Nanoparticle studied | Function | Cell type |
|---|---|---|---|
| Manickam et al. [ | Iron oxide nanoparticles | Oxidant by Nox 4 overexpression | Myocardium from mice |
| Petty [ | WO3-Pt nanoparticles | Oxidant. NADPH oxidase biomimetic | Tumor cells |
| Sun et al. [ | Silver nanoparticles | Oxidant by increasing Nox 4 expression | Human umbilical vein endothelial cells |
| Ramirez-Lee et al. [ | Silver nanoparticles | Increase of hypertension due to a decrease in NO levels | Myocardium from rats |
| T. Yu et al. [ | PLGA nanoparticles | Carrier. Treatment for hypertension | Hypertensive rats |
| Le et al. [ | PLGA nanoparticles | ROS scavenger at vascular level and endothelial protector | Human umbilical vascular endothelial cells |
| Reddy and Labhasetwar [ | PLGA nanoparticles | SOD carrier | Rat focal cerebral ischemia/reperfusion injury |
| Hennig et al. [ | PEGylated quantum dots | Carrier of angiotensin II | AT1R-expressing cells |
| C. Guo et al. [ | Silica nanoparticles | Endothelial injury induced by mitochondrial dysfunction | Human endothelial cells |
| Farooq et al. [ | Silica nanoparticles | Endothelial dysfunction induced by oxidative stress | Aorta from rat |
| D. Lee et al. [ | PVAX | Antioxidant, anti-inflammatory, and antiapoptotic activity | Hind-limb and liver from an ischemia/reperfusion model in mice |
| Marrache and Dhar [ | PLGA-b-PEG-TPP nanoparticles | Nanocarriers | Mitochondria-acting therapeutics |
| Marushima et al. [ | RNP | Neuroprotective agent due to its ability to scavenge free radicals | Middle cerebral artery from rats with cerebral ischemia/reperfusion injury |
| Chonpathompikunlert et al. [ | Redox-polymer nanotherapeutics | Treatment of the neurodegenerative diseases | Brain from SAMP8 mice |
| Ciofani et al. [ | Nanoceria | SOD and catalase mimetic | PC12 neuronal-like cells |
| Estevez et al. [ | Nanoceria | Reduction of oxidative and nitrosative damage after stroke | Mouse hippocampal brain slice model of ischemia |
| Hirst et al. [ | Nanoceria | Anti-inflammatory and NO scavenger | Murine macrophages |
| Niu et al. [ | Nanoceria | Antioxidant | Cultured rat H9c2 cardiomyocytes |
| Niu et al. [ | Nanoceria | Antioxidant and anti-inflammatory | Murine myocardium |
| Gojova et al. [ | Nanoceria | Inflammatory effect | Human aortic endothelial cells |
| Wingard et al. [ | Nanoceria | Vascular dysfunction | Aorta from mice |
| Minarchick et al. [ | Nanoceria | Vascular antioxidant | Arterioles from hypertensive rats |
| Minarchick et al. [ | Nanoceria | Prooxidant. Microvascular dysfunction | Arteriola from rats |
| Kennedy et al. [ | Iron oxide, yttrium oxide, cerium oxide, zinc oxide | Proinflammatory | Human vascular endothelial cell line |
| Park et al. [ | Nanoparticles based on polyoxalate | Antioxidant and anti-inflammatory | Doxorubicin-treated mice heart |
| Seshadri et al. [ | Polyketal particles | SOD carrier | Rat myocardium |
WO3-Pt: platinum tungsten oxide; PLGA: copolymer poly (lactic-co-glycolic acid); SOD: superoxide dismutase; PEG: polyethylene glycol; PVAX: copolyoxalate containing vanillyl alcohol (VA); RNP: radical-containing-nanoparticles.